Coherus Oncology (CHRS) EBT (2013 - 2026)
Coherus Oncology (CHRS) posted EBT of -$36.9 million for Q1 2026, up 20.31% sequentially from -$46.3 million in Q4 2025, and up 22.07% YoY from -$30.3 million in Q1 2025.
Coherus Oncology (CHRS) EBT (2013 - 2026) Analysis & Trends
Coherus Oncology has reported EBT for 14 years, with the latest figure at -$36.9 million in Q1 2026.
- Quarterly EBT rose 22.07% year-over-year to -$36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$172.7 million (up 11.88% YoY) and the FY2025 annual result came in at -$183.1 million, up 14.98% from the prior year.
- EBT advanced to -$36.9 million in Q1 2026 per CHRS's latest filing, from -$46.3 million in the prior quarter.
- Over five years, EBT peaked at -$36.9 million in Q1 2026 and troughed at -$96.1 million in Q1 2022.
- A 5-year average of -$56.9 million and a median of -$47.6 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT plunged 124.9% in 2022, then soared 53.81% in 2023.
- Over 5 years, EBT stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then surged by 42.13% to -$46.1 million in 2024, then fell by 0.55% to -$46.3 million in 2025, then advanced by 20.31% to -$36.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$36.9 million, -$46.3 million, and -$44.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -33.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.35 Mn |
| Mar 31, 2026 | -36.94 Mn |
| Dec 31, 2025 | -46.35 Mn |
| Sep 30, 2025 | -44.52 Mn |
| Jun 30, 2025 | -44.86 Mn |
| Mar 31, 2025 | -47.40 Mn |
| Dec 31, 2024 | -46.09 Mn |
| Sep 30, 2024 | -47.60 Mn |
| Jun 30, 2024 | -54.85 Mn |
| Mar 31, 2024 | -68.04 Mn |
| Dec 31, 2023 | -79.65 Mn |
| Sep 30, 2023 | -40.02 Mn |
| Jun 30, 2023 | -42.87 Mn |
| Mar 31, 2023 | -75.73 Mn |
| Dec 31, 2022 | -58.87 Mn |
| Sep 30, 2022 | -86.65 Mn |
| Jun 30, 2022 | -50.15 Mn |
| Mar 31, 2022 | -96.08 Mn |
| Dec 31, 2021 | -45.68 Mn |
| Sep 30, 2021 | -38.53 Mn |